An open, observational, non-interventional, multicenter study of the effect of Kagocel® on the quality of life of patients with acute respiratory viral infections in realworld clinical practice in the Republic of Kazakhstan
- 25 December 2025
- journal article
- Published by Publishing House OKI in Real-World Data & Evidence
- Vol. 5 (4) , 19-28
Abstract
Relevance. Acute respiratory infections are the leading cause of disease worldwide. Kagocel® is a synthetic antiviral agent indicated for influenza and other acute respiratory viral infections (ARVI). It induces the production of interferon, thereby enhancing the immune response to viral pathogens. Objective. To evaluate changes in quality of life and symptom dynamics when prescribing Kagocel® to patients with ARVI. Materials and methods. This open, multicenter, observational, non-interventional study enrolled 1000 adult patients, 467 with mild and 533 with moderate ARVI. All patients were prescribed Kagocel® tablets for 4 days within 24–72 h from the ARVI symptom onset. Results. In patients with mild ARVI, a statistically significant (p Conclusion. The oral administration of Kagocel® to ambulatory patients with mild to moderate ARVI was effective and safe; therefore, it may be routinely recommended.Keywords
This publication has 8 references indexed in Scilit:
- Disease burden and high-risk populations for complications in patients with acute respiratory infections: a scoping reviewFrontiers in Medicine, 2024
- Trends and determinants of acute respiratory infection symptoms among under-five children in Cambodia: Analysis of 2000 to 2014 Cambodia demographic and health surveysPLOS Global Public Health, 2023
- Costs of management of acute respiratory infections in older adults: A systematic review and meta-analysisJournal of Global Health, 2022
- ANTIVIRAL EFFECT OF «KAGOCEL» SUBSTANCE IN VITRO ON INFLUENZA VIRUSES H1N1, H1N1PDM09 AND H3N2Problems of Virology, 2019
- Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet Infectious Diseases, 2018
- Safety of the Russian antiviral drug KagocelTerapevticheskii arkhiv, 2017
- Department of ErrorThe Lancet, 2017
- Therapy of acute respiratory diseases with those operating under conditions of low intensity occupational hazardsConsilium Medicum, 2016